Enzalutamide in Metastatic Prostate Cancer before ChemotherapyTomasz M. Beer, Bertrand Tombal, Ian D. Davis et al.|New England Journal of Medicine|2014Cited by 3k
Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|New England Journal of Medicine|2012Cited by 2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Johann S. de Bono, Howard I. Scher et al.|The Lancet Oncology|2012Cited by 1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015Cited by 1.4k
Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseFred Saad, Robert E. Coleman|Cancer|2007Cited by 658